Calidi Biotherapeutics, Inc.
Biological Products, (No Diagnostic Substances) · SAN DIEGO · CA
Moderate confidence (50%)
Updated Oct 8, 2026, 12:04 AM
What is happening
Derived by rule set status-rules-2026.09.7
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
Latest material event: Calidi Biotherapeutics, Inc. received a delisting notice from its exchange (Sep 21, 2026)
Timeline
Every material event, newest first. History is never overwritten.
Calidi Biotherapeutics, Inc. received a delisting notice from its exchange
Sep 21, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 21, 2026, Calidi Biotherapeutics, Inc. (the Company ) received a letter (the Notice ) from staff of NYSE American LLC (the Exchange ). The Notice stated that the Company is not in compliance with the stockholders equity continued listing standard in Section 1003(a)(ii) of the NYSE American Company Guide (the Company Guide ). Section 1003(a)(ii) requires a listed company to maintain stockholders equity of $4.0 million or more if it has reported losses from continuing oper…”
Company information
- Founded
- —
- Employees (estimate)
- —
- Industry
- Biological Products, (No Diagnostic Substances)
- Subindustry
- —
- Listing
- SEC lists the tickers CLDI and CLDWW on NYSE and OTC.
- SEC CIK
- 0001855485
- Website
- —
- —
- Headquarters
- SAN DIEGO, CA
- Also known as
- Calidi Biotherapeutics, Inc., First Light Acquisition Group, Inc.
- Legal entities
- Calidi Biotherapeutics, Inc.
Sources
Every material source used to build this profile.
SEC Company Submissions (TIER 1 · UNVERIFIED)
Calidi Biotherapeutics, Inc. — Biological Products, (No Diagnostic Substances) (SIC 2836) — SAN DIEGO, CA
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 21, 2026, Calidi Biotherapeutics, Inc. (the Company ) received a letter (the Notice ) from staff of NYSE American LLC (the Exchange ). The Notice stated that the Company is not in compliance with the stockholders equity continued listing standard in Section 1003(a)(ii) of the NYSE American Company Guide (the Company Guide ). Section 1003(a)(ii) requires a listed company to maintain stockholders equity of $4.0 million or more if it has reported losses from continuing oper…
View source record
Status history
Every derived status, with the rule that produced it.
- UNKNOWN → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 27, 2026, 12:10 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.